Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11356715rdf:typepubmed:Citationlld:pubmed
pubmed-article:11356715lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:11356715lifeskim:mentionsumls-concept:C0037657lld:lifeskim
pubmed-article:11356715lifeskim:mentionsumls-concept:C0123258lld:lifeskim
pubmed-article:11356715lifeskim:mentionsumls-concept:C0678812lld:lifeskim
pubmed-article:11356715lifeskim:mentionsumls-concept:C0699812lld:lifeskim
pubmed-article:11356715lifeskim:mentionsumls-concept:C1167622lld:lifeskim
pubmed-article:11356715lifeskim:mentionsumls-concept:C0005508lld:lifeskim
pubmed-article:11356715lifeskim:mentionsumls-concept:C0549193lld:lifeskim
pubmed-article:11356715lifeskim:mentionsumls-concept:C0441712lld:lifeskim
pubmed-article:11356715pubmed:issue6lld:pubmed
pubmed-article:11356715pubmed:dateCreated2001-5-17lld:pubmed
pubmed-article:11356715pubmed:abstractTextInsulin-like growth factor (IGF)-binding protein-4 (IGFBP-4) is a potent inhibitor of IGF actions in vitro. However, we found that systemic administration of IGFBP-4 at pharmacological doses caused a significant increase in bone formation parameters in mice by a mechanism that may involve increased IGF bioavailability via proteolysis of IGFBP-4. To evaluate the hypothesis that proteolysis of IGFBP-4 is essential for the stimulatory effects of systemically administered IGFBP-4, we produced wild-type, protease-resistant, and IGFBP-4 proteolytic fragments and evaluated their effects using biochemical markers. Protease-resistant IGFBP-4 was more potent than wild-type IGFBP-4 in inhibiting IGF-I-induced mouse osteoblast cell proliferation in vitro and in inhibiting IGF-I-induced increase in alkaline phosphatase (ALP) activity in bone extract after local administration in vivo. Systemic administration of wild-type IGFBP-4, but not protease-resistant IGFBP-4, increased serum osteocalcin, serum ALP, and ALP in skeletal extracts in a dose-dependent manner, with a maximal effect of 40% (P < 0.05) at 1.25 nmol/mouse. Systemic administration of wild-type, but not protease-resistant, IGFBP-4 increased free IGF-I levels in serum in normal mice. IGF-I, but not wild-type IGFBP-4, increased bone formation parameters in IGF-I-deficient mice. This study demonstrates that systemic administration of IGFBP-4 increases bone formation parameters in mice by increasing IGF bioavailability in the circulation via an IGFBP-4 protease-dependent mechanism.lld:pubmed
pubmed-article:11356715pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11356715pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11356715pubmed:languageenglld:pubmed
pubmed-article:11356715pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11356715pubmed:citationSubsetAIMlld:pubmed
pubmed-article:11356715pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11356715pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11356715pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11356715pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11356715pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11356715pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11356715pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11356715pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11356715pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11356715pubmed:statusMEDLINElld:pubmed
pubmed-article:11356715pubmed:monthJunlld:pubmed
pubmed-article:11356715pubmed:issn0013-7227lld:pubmed
pubmed-article:11356715pubmed:authorpubmed-author:MohanSSlld:pubmed
pubmed-article:11356715pubmed:authorpubmed-author:BaylinkD JDJlld:pubmed
pubmed-article:11356715pubmed:authorpubmed-author:SrivastavaA...lld:pubmed
pubmed-article:11356715pubmed:authorpubmed-author:RichmanCClld:pubmed
pubmed-article:11356715pubmed:authorpubmed-author:MiyakoshiNNlld:pubmed
pubmed-article:11356715pubmed:authorpubmed-author:QiuSSlld:pubmed
pubmed-article:11356715pubmed:authorpubmed-author:KasukawaYYlld:pubmed
pubmed-article:11356715pubmed:issnTypePrintlld:pubmed
pubmed-article:11356715pubmed:volume142lld:pubmed
pubmed-article:11356715pubmed:ownerNLMlld:pubmed
pubmed-article:11356715pubmed:authorsCompleteYlld:pubmed
pubmed-article:11356715pubmed:pagination2641-8lld:pubmed
pubmed-article:11356715pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:11356715pubmed:meshHeadingpubmed-meshheading:11356715...lld:pubmed
pubmed-article:11356715pubmed:meshHeadingpubmed-meshheading:11356715...lld:pubmed
pubmed-article:11356715pubmed:meshHeadingpubmed-meshheading:11356715...lld:pubmed
pubmed-article:11356715pubmed:meshHeadingpubmed-meshheading:11356715...lld:pubmed
pubmed-article:11356715pubmed:meshHeadingpubmed-meshheading:11356715...lld:pubmed
pubmed-article:11356715pubmed:meshHeadingpubmed-meshheading:11356715...lld:pubmed
pubmed-article:11356715pubmed:meshHeadingpubmed-meshheading:11356715...lld:pubmed
pubmed-article:11356715pubmed:meshHeadingpubmed-meshheading:11356715...lld:pubmed
pubmed-article:11356715pubmed:meshHeadingpubmed-meshheading:11356715...lld:pubmed
pubmed-article:11356715pubmed:meshHeadingpubmed-meshheading:11356715...lld:pubmed
pubmed-article:11356715pubmed:meshHeadingpubmed-meshheading:11356715...lld:pubmed
pubmed-article:11356715pubmed:meshHeadingpubmed-meshheading:11356715...lld:pubmed
pubmed-article:11356715pubmed:meshHeadingpubmed-meshheading:11356715...lld:pubmed
pubmed-article:11356715pubmed:meshHeadingpubmed-meshheading:11356715...lld:pubmed
pubmed-article:11356715pubmed:meshHeadingpubmed-meshheading:11356715...lld:pubmed
pubmed-article:11356715pubmed:meshHeadingpubmed-meshheading:11356715...lld:pubmed
pubmed-article:11356715pubmed:meshHeadingpubmed-meshheading:11356715...lld:pubmed
pubmed-article:11356715pubmed:meshHeadingpubmed-meshheading:11356715...lld:pubmed
pubmed-article:11356715pubmed:meshHeadingpubmed-meshheading:11356715...lld:pubmed
pubmed-article:11356715pubmed:meshHeadingpubmed-meshheading:11356715...lld:pubmed
pubmed-article:11356715pubmed:year2001lld:pubmed
pubmed-article:11356715pubmed:articleTitleSystemic administration of insulin-like growth factor (IGF)-binding protein-4 (IGFBP-4) increases bone formation parameters in mice by increasing IGF bioavailability via an IGFBP-4 protease-dependent mechanism.lld:pubmed
pubmed-article:11356715pubmed:affiliationMusculoskeletal Disease Center, J. L. Pettis Veterans Administration Medical Center, Loma Linda, California 92357, USA.lld:pubmed
pubmed-article:11356715pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11356715pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:11356715pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11356715lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11356715lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11356715lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11356715lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11356715lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11356715lld:pubmed